Press Releases
Oct. 8, 2014 biOasis Engages Willow Tree Group to Assist with Global Business Development Activities
Vancouver, British Columbia–(Business Wire)– biOasis Technologies, Inc.(OTCQX:BIOAF; TSX.V:BTI), the pioneering biopharmaceutical company focused on the delivery of therapeutic drugs across the blood-brain barrier (“BBB”), engages Willow Tree Capital Group of Toronto, Canada. Willow Tree’s full service team of healthcare, scientific and business specialists provides a comprehensive suite of business development services to life science companies… Read more »
Sep. 19, 2014 biOasis Initiates MPS II Study with Renowned Lysosomal Storage Disease Expert Dr. Maurizio Scarpa and The Brains for Brain Foundation
One of the most challenging aspects of treating Lysosomal Storage Diseases is the transport of the required enzymes across the Blood-Brain Barrier and into the Central Nervous System.
Sep. 10, 2014 biOasis Advances Its Lysosomal Storage Disease Program with a Knockout Model for Sandhoff Disease
“biOasis initiates pivotal study using a knockout model for Sandhoff Lysosomal Storage Disease”
Sep. 5, 2014 biOasis Announces NSERC Grant to The University of British Columbia in Support of Collaborative R&D Work with biOasis
Vancouver, British Columbia–(Business Wire)– biOasis Technologies, Inc. (OTCQX:BIOAF; TSXV:BTI), announces that the Natural Sciences and Engineering Research Council of Canada (“NSERC”) has awarded a grant to the University of British Columbia (“UBC”) in support of the university’s collaborative research and development programs with biOasis Technologies Inc. The University and biOasis continue to develop biOasis’ extensive… Read more »
Aug. 30, 2014 biOasis Closes Non-Brokered Private Placement for $1,609,753.15 Gross Proceeds
Vancouver, British Columbia–(Business Wire)– biOasis Technologies Inc. (TSX.V: BTI) (the “Company”) is please to announce it has closed its non-brokered private placement announced on August 8th, 2014. The Company has issued 1,694,447 units (each a “Unit”), including an over allotment of 94,477 Units, at a price of CDN$0.95 per unit, for gross proceeds of CDN$1,609,753.15.… Read more »
Aug. 9, 2014 biOasis Announces Non-Brokered Private Placement
Vancouver, British Columbia–(Business Wire)– biOasis Technologies Inc. (TSX.V: BTI)(OTCQX: BIOAF)(the “Company”) announces a non-brokered private placement of up to 1,600,000 units (each a “Unit”) at a price of $0.95 per Unit of gross proceeds of up to $1,520,000 with an overallotment of up to 20%. Each Unit will consist of one common share and one… Read more »
Jul. 26, 2014 biOasis Releases Quantitative Results: siRNA-Transcendpep reduces target gene expression in the brain
The Ability to Deliver siRNAs to the Brain Represents a Major Advancement in the Potential Treatment of CNS Disorders by Modifying Expression of Disease-Causing Genes – Results from initial experiments show modification of gene expression by 40% to 50%
Jun. 21, 2014 biOasis Appoints New Chief Financial Officer and Corporate Secretary
Vancouver, British Columbia–(Business Wire)– biOasis Technologies Inc. (OTCQX:BIOAF) (TSX.V:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, announces the appointment of Ms. Judi Dalling as its Chief Financial Officer and Corporate Secretary effective immediately. Ms. Dalling is an experienced professional, a graduate of The University of… Read more »
Jun. 17, 2014 biOasis Enters Investor Relations Agreement with Gale Capital Corporation
Vancouver, British Columbia–(Business Wire)– biOasis Technologies Inc. (TSX.V:BTI) (OTCQX: BIOAF) (the “Company”) is pleased to announce that is has retained Gale Capital Corporation (“Gale Capital”) effective June 15, 2014 to assist the Company with its shareholder relations activities and investor awareness program. Gale Capital will help by cultivating productive dialogue with analysts, brokers, potential investors… Read more »
May. 8, 2014 biOasis Secures DTC Eligibility
Vancouver, British Columbia–(Business Wire)– biOasis Technologies Inc. (OTCQX:BIOAF) (TSX.V:BTI), a pioneering biopharmaceutical company focused on overcoming the limitations of therapeutic drug delivery across the blood-brain barrier, today announced that it has secured DTC eligibility by The Depository Trust Company (DTC) for its shares traded on the OTCQX® under the symbol BIOAF. The DTC is a… Read more »